drugset / Trial / NCT05748977
Short Acting Agents Vs Long Acting in Frequent Excerbator COPD Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
Chronic obstructive pulmonary disease is heterogeneous lung condition characterized by chronic respiratory symptoms (dyspnea, cough, sputum production, exacerbations) due to abnormalities of the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive ,airflow obstruction. There are network meta analysis to compare the efficacy and safety of short acting bronchodilators Vs long acting agents in treatment of COPD
Timeline
- Start
- 2023-02-20
- Primary completion
- 2024-02-20
- Completion
- 2024-03-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Beclomethasone | Small molecule | — | Inhaled |
| Subject | Fenotereol | Unknown | — | Inhaled |
| Subject | Fluticasone | Other / unclassified | — | Inhaled |
| Subject | Ipratroium | Unknown | — | Inhaled |
| Subject | Salmeterol | Other / unclassified | — | Inhaled |
| Subject | Tiotropium | Other / unclassified | — | Inhaled |